AnaptysBio, Inc. ANAB 深 滬
已收盤 11-14 16:00:00 美东时间
33.82
+0.560
+1.68%
華盛通- 最 高34.56
- 今 開33.08
- 成交量 74.60万股
- 最 低 32.96
- 昨 收 33.26
- 總市值 9.47亿
- 52周最高 40.96
- 市盈率 靜 --
- 換手率 2.66%
- 52周最低 12.21
- 委 比 55.16%
- 總股本 2799.70万
- 歷史最高 134.00
- 量 比 0.68
- 振 幅 4.81%
- 歷史最低 10.00
- 每 手 1
- 風險率 5.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs.
11-11 01:30
Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $36
Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $20 to $36.
11-11 00:11
AnaptysBio posts mid-stage trial setback for lead asset in ulcerative colitis
AnaptysBio (ANAB) on Monday announced a failure in a Phase 2 trial for its lead candidate rosnilimab in ulcerative colitis, an inflammatory bowel disorder affecting the large intestine and rectum. Cit...
11-10 22:56
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
AnaptysBio Q3 EPS $0.52 Beats $(1.42) Estimate, Sales $76.320M Beat $15.811M Estimate
AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $(1.42) by 136.65 percent. This is a 145.61 percent increase over losses of $(1.14) per share from the
11-05 05:38
Anaptys Announces Participation in November Investor Conferences
AnaptysBio, a clinical-stage biotechnology company, announced that its CEO and executive team will participate in multiple investor conferences in November 2025. Key events include the TD Cowen Immunology & Inflammation Summit (Virtual) on Nov. 12, the Guggenheim Healthcare Innovation Conference in Boston on Nov. 12, the Stifel Healthcare Conference in New York on Nov. 13, and the Jefferies Global Healthcare Conference in London on Nov. 17. Each ...
11-04 21:15
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $55 to $80.
10-30 00:53
